Symbolbild · KI-generiert
Bright Minds Biosciences Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, PWS, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Company description as published by the issuer via Canadian Securities Exchange.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Bright Minds Biosciences Inc. | DRUG | CSE | 715 Mio. USD |
| Pharming Group N.V. | PHAR | NASDAQ | 712 Mio. USD |
| Aura Biosciences, Inc. | AURA | NASDAQ | 725 Mio. USD |
| Monopar Therapeutics Inc. | MNPR | NASDAQ | 726 Mio. USD |
| Aclaris Therapeutics, Inc. | ACRS | NASDAQ | 726 Mio. USD |
| Faeth Therapeutics, Inc. | FTH | NASDAQ | 702 Mio. USD |
| Phathom Pharmaceuticals, Inc. | PHAT | NASDAQ | 698 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.